Chronic Myeloid Leukemia (CML) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
-1.jpg)
Chronic myeloid leukemia (CML) is also known as chronic myelogenous leukemia. It's a type of cancer that starts in certain blood-forming cells of the bone marrow. In CML, a genetic change takes place in an early (immature) version of myeloid cells -- the cells that make red blood cells, platelets, and most types of white blood cells (except lymphocytes). This change forms an abnormal gene called BCR-ABL, which turns the cell into a CML cell. The leukemia cells grow and divide, building up in the bone marrow and spilling over into the blood. In time, the cells can also settle in other parts of the body, including the spleen. CML is fairly slow-growing leukemia, but it can change into fast-growing acute leukemia that's hard to treat. Morphologically, CML is characterized by the hypercellular bone marrow, unregulated growth of myeloid cells (neutrophils, eosinophils, basophils, and megakaryocytes) resulting in an abnormally high level of morphologically terminally differentiated granulocytes, as well as myeloid precursor cells in the blood and is associated with splenic enlargement in >60% of affected children.
·
The incidence of Chronic Myeloid Leukemia
(CML) is 1 to 1.5 cases per 1 million children which is very rare in the first
20 years of life.
Thelansis’s “Chronic Myeloid Leukemia
(CML) Market Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2021 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Chronic
Myeloid Leukemia (CML) treatment modalities options for eight major markets
(USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Chronic Myeloid Leukemia (CML) across 8 MM market from the centre of
Excellence/ Public/ Private hospitals participated in the study. Insights
around current treatment landscape, epidemiology, clinical characteristics,
future treatment paradigm, and Unmet needs.
Chronic Myeloid Leukemia (CML) Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment